The residual DNA testing market size was valued at USD 328.87 million in 2025 and is projected to grow from USD 350.08 million in 2026 to USD 584.86 million by 2034, registering a CAGR of 6.63% during the forecast period (2026–2034). North America dominated the residual DNA testing marketwith a marketshare of 44.29% in 2025.
Residual DNA testing is a quality control process used to detect and quantify trace amounts of host cell DNA remaining in biologics, vaccines, cell and gene therapies, and other biopharmaceutical products. The testing ensures product safety, regulatory compliance, and adherence to established quality standards by confirming that residual DNA levels remain within acceptable limits. It is widely applied throughout biopharmaceutical development, manufacturing, and product release testing.
The residual DNA testing market demand is increasing due to rapid growth in biologics and advanced therapies, stringent regulatory requirements, and expanding biopharmaceutical manufacturing activities. Manufacturers are investing in testing technologies to improve product quality and compliance. Continuous technological advancements and rising investments in biotechnology research are further supporting residual DNA testing market growth.
The residual DNA testing market is witnessing a shift toward advanced analytical methods that provide higher sensitivity and accuracy in detecting trace host-cell DNA contamination in biologics and gene therapies. Manufacturers are increasingly adopting next-generation sequencing and digital PCR-based approaches to improve quality control, reduce testing limitations, and support regulatory compliance. For example, companies such as QIAGEN and Thermo Fisher Scientific are expanding molecular testing solutions that enable precise nucleic acid quantification for biopharmaceutical applications.
The residual DNA testing market is moving toward automated and standardized testing workflows as biopharmaceutical manufacturers seek faster turnaround times and improved laboratory efficiency. Automated sample preparation, data analysis, and integrated analytical platforms are reducing manual intervention while improving consistency across testing processes. For example, Bio-Rad Laboratories’ digital PCR platforms support sensitive DNA quantification workflows used in complex biological testing applications, helping laboratories enhance accuracy and operational efficiency.
The residual DNA testing market forecasts continued investment activity driven by the growing development of biologics, cell and gene therapies, and mRNA-based products requiring stringent quality control and regulatory compliance. Companies are expected to increase investments in advanced analytical platforms, automation, and high-sensitivity DNA quantification technologies to improve testing accuracy, throughput, and manufacturing efficiency.
Key Investment and Fundin Activities in Residual DNA Testing Market I
One Biosciences
~USD 17.5 Million (Series A)
In July 2025, One Biosciences secured approximately USD 17.5 million to accelerate development of its single-cell analytical platform and expand partnerships with pharmaceutical and biotechnology companies for advanced molecular characterization and quality assessment.
Portal Biotech
USD 35 Million (Series A)
InJune 2025, Portal Biotech raised USD 35 to commercialize its nanopore-based protein characterization platform, expand R&D capabilities, and deepen collaborations with pharmaceutical and biotechnology companies, supporting advanced analytical technologies used in biologics quality control.
Growing Adoption of Cell & Gene Therapies and Increasing Shift toward Continuous Bioprocessing Drives Market
The expansion of cell and gene therapy manufacturing increases the need for highly sensitive residual DNA testing methods to detect trace genetic impurities from production systems. These therapies involve complex biological processes that require strict monitoring of host cell DNA contamination before clinical use. For example, the FDA approved five cell and gene therapy products in 2025, including therapies such as ITVISMA from Novartis Gene Therapies and WASKYRA, highlighting the continued commercialization of advanced therapies that require rigorous impurity testing and quality control. Gene therapy manufacturers use quantitative PCR- and digital PCR-based assays to verify residual DNA clearance during viral vector production. The increasing commercialization of advanced therapies drives demand for specialized testing platforms and improved batch release confidence.
The adoption of continuous manufacturing and single-use bioprocessing systems increases the need for frequent and reliable residual DNA monitoring to maintain process consistency. These manufacturing approaches improve efficiency but require enhanced analytical controls to detect impurities introduced during production cycles. For example, biopharmaceutical companies using bioreactors perform residual DNA analysis to validate process performance and product purity. The growing transition toward flexible manufacturing models drives demand for automated and high-throughput residual DNA testing solutions across biologics production facilities.
High Cost of Advanced Molecular Testing Platforms and Complex Method Validation Requirements Restrain Market Expansion
Residual DNA testing requires sophisticated analytical platforms such as digital PCR, next-generation sequencing systems, and highly validated reference standards, which involve significant capital and operational costs. Smaller biopharmaceutical manufacturers and contract testing laboratories may face challenges in investing in these advanced technologies due to high equipment costs, assay development expenses, and maintenance requirements. For example, implementation of digital PCR workflows requires specialized instruments, trained personnel, and validated protocols, limiting adoption among resource-constrained laboratories.
Residual DNA testing methods require extensive validation to demonstrate accuracy, sensitivity, specificity, and compliance with regulatory expectations across different biologics manufacturing processes. Variations in host-cell systems, production platforms, and assay requirements make standardization challenging for manufacturers. For example, residual DNA testing protocols for CHO cell-derived monoclonal antibodies may require different validation approaches compared with viral vector-based gene therapies. This complexity increases development timelines and testing costs, slowing broader adoption of advanced residual DNA testing solutions.
Adoption of Residual DNA Testing for RNA Therapeutics Manufacturing and Development of Platform Specific Residual DNA Assays Offer Growth Opportunities to Market Players
The rapid commercialization of mRNA vaccines and RNA-based therapeutics is creating opportunities to develop residual DNA assays specifically for plasmid DNA clearance during in vitro transcription manufacturing. Unlike conventional biologics, RNA therapeutics require monitoring of residual template DNA at extremely low concentrations before product release. As more companies establish large-scale mRNA manufacturing facilities, demand for validated, high-sensitivity residual DNA testing kits designed for RNA production workflows is expected to increase significantly.
The growing use of alternative expression systems such as HEK293, Sf9 insect cells, Vero cells, and yeast is creating demand for customized residual DNA assays tailored to individual manufacturing platforms. Most commercial assays have traditionally focused on CHO- and E. coli-derived products, leaving an unmet need for validated platform-specific solutions. Companies that develop standardized assays and certified reference materials for emerging host-cell systems can gain a competitive advantage as biologics manufacturing becomes increasingly diversified.
Absence of Universal Assays and Difficulty in Establishing Matrix Specific Reference Standards Challenges Market Growth
A major challenge for the residual DNA testing market is the absence of universally applicable assays that perform consistently across different host cell expression systems and advanced therapy manufacturing platforms. Residual DNA characteristics vary significantly between CHO cells, HEK293 cells, Vero cells, E. coli, yeast, and insect cells, requiring platform-specific assay design and validation. This increases assay development time, regulatory documentation, and testing costs, limiting workflow standardization for manufacturers operating multiple production platforms.
Another challenge for the residual DNA testing market is the lack of universally accepted matrix-specific reference standards for different biological products and manufacturing processes. Variations in formulations, excipients, purification methods, and host-cell expression systems can influence DNA extraction efficiency and assay performance, making it difficult to achieve comparable results across laboratories.
Based on product & service, the consumables segment dominates the market with a revenue share of 40.24% in 2025, owing to the recurring requirement for extraction kits, PCR reagents, primers, and certified reference standards in every residual DNA testing workflow. Batch-wise quality control and product release testing further sustain continuous consumable demand across biopharmaceutical manufacturing facilities.
The services segment is expected to grow at a CAGR of around 7.31% during the forecast period due to increasing outsourcing of custom assay development, method validation, and regulatory-compliant testing by emerging biotechnology companies. Growing preference for external analytical expertise enables manufacturers to reduce infrastructure investments while accelerating biologics development timelines.
In 2025, final product release testing accounted for a share of 45.13% in the residual DNA testing market, as every commercial biologic batch requires validated residual DNA analysis before regulatory release. Mandatory lot certification and product safety verification make final release testing a critical quality assurance requirement for manufacturers.
The bulk testing segment is expected to grow at a CAGR of 6.97% during the forecast period, driven by increasing emphasis on detecting residual DNA impurities before final fill-finish operations. Early-stage testing reduces batch rejection risks and supports efficient process optimization during commercial biologics manufacturing.
By technology, polymerase chain reaction accounted for a share of 42.26% in 2025 due to its rapid turnaround time, established regulatory acceptance, and compatibility with validated quality control workflows. The technology also offers cost-effective and highly reproducible residual DNA quantification across multiple biologics manufacturing platforms.
The next-generation sequencing segment is expected to grow at a CAGR of 7.48% during the forecast period, driven by increasing demand for sequence-level characterization of residual DNA fragments and unknown genetic impurities. Advanced biologics and gene therapies continue expanding the need for comprehensive genomic impurity profiling.
By application, the monoclonal antibodies segment accounted for a share of 45.34% in 2025 due to large-scale commercial production requiring routine residual DNA testing across multiple manufacturing batches. Standardized CHO cell-based production processes further support widespread implementation of validated host cell DNA quantification assays.
The cell & gene therapy segment is projected to grow at a CAGR of 7.60% during the forecast period. increasing production of viral vector and engineered cell therapies requiring ultra-sensitive residual DNA detection. Stringent impurity control requirements continue accelerating adoption of advanced molecular testing technologies.
Based on end user, pharmaceutical & biotechnology companies accounted for a share of 58.16% in 2025, owing to expanding in-house biologics manufacturing and dedicated quality control laboratories performing routine residual DNA analysis. Continuous investments in internal analytical capabilities further strengthen adoption of advanced testing platforms.
The CROs & CMOs segment is projected to grow at a CAGR of 7.65% during the forecast period, fueled by the rising outsourcing of analytical testing by small- and mid-sized biotechnology companies seeking flexible development support. Expansion of integrated biologics manufacturing services continues driving demand for specialized residual DNA testing providers.
North America: Market Dominance Led by Increasing Commercialization of Cell & Gene Therapies and Advanced Analytical Testing Infrastructure
The North America residual DNA testing market accounted for the largest regional share of 44.29% in 2025, driven by the presence of an established biopharmaceutical manufacturing ecosystem, stringent regulatory expectations for biologics quality control, and the increasing commercialization of cell and gene therapies. The region benefits from advanced analytical testing infrastructure, leading biotechnology companies, and extensive R&D investments. The US continues to dominate biologics innovation, with hundreds of biologic and advanced therapy candidates progressing through clinical and commercial manufacturing, supporting sustained demand for residual DNA testing.
The US residual DNA testing market was valued at USD 127.30 million in 2025, driven by commercial biologics production, increasing approvals of advanced therapies, and widespread adoption of molecular quality control technologies. Biopharmaceutical manufacturers are continuously investing in highly sensitive analytical platforms to ensure compliance with FDA requirements for host cell DNA impurities. The country's strong presence of biologics developers, contract development and manufacturing organizations, and specialized analytical testing laboratories continues to accelerate demand for residual DNA testing across commercial manufacturing and product release workflows.
The Canada residual DNA testing market size was valued at USD 18.35 million in 2025, supported by expanding biologics research, increasing investment in domestic biomanufacturing capacity, and growing emphasis on pharmaceutical quality assurance. Canadian biotechnology companies and research organizations are strengthening analytical capabilities to support vaccine, recombinant protein, and advanced therapy development. Government initiatives promoting life sciences innovation and expansion of GMP-compliant manufacturing facilities continue creating favorable conditions for adoption of residual DNA testing technologies across the country's biopharmaceutical sector.
Asia Pacific: Fastest Growth Driven by Expansion of Domestic Biologics Manufacturing and Rising Innovations in Regenerative Medicine
The Asia Pacific residual DNA testing market is expected to grow at a CAGR of 8.22% during the forecast period, showcasing the fastest regional growth. Growth is driven by rapid expansion of domestic biologics manufacturing, increasing investments in vaccine self-sufficiency, and strengthening regulatory frameworks for biopharmaceutical quality control. Regional governments are promoting local production of biologics and advanced therapies through dedicated biotechnology initiatives, increasing the need for validated analytical testing. The growing presence of regional CDMOs and biopharmaceutical innovation hubs is further accelerating the adoption of residual DNA testing technologies across the Asia Pacific.
The China residual DNA testing market size was valued at USD 19.10 million in 2025, supported by rapid expansion of domestic CDMO capacity and increasing commercialization of locally developed monoclonal antibodies and biosimilars. Chinese biopharmaceutical companies are investing heavily in analytical quality control capabilities to support global regulatory submissions and international product exports. Expansion of large-scale biologics manufacturing clusters in Shanghai, Suzhou, and Guangzhou continues driving demand for advanced residual DNA testing solutions.
The India residual DNA testing market size was valued at USD 9.77 million in 2025, fueled by its emergence as a global contract biopharmaceutical manufacturing destination and growing production of recombinant vaccines and biosimilars. Increasing investments in GMP-compliant biologics facilities and expansion of analytical testing laboratories are strengthening demand for residual DNA analysis. Rising collaborations between domestic biotechnology companies and multinational pharmaceutical firms are further supporting adoption of advanced molecular quality control technologies.
The Japan residual DNA testing market was valued at USD 11.27 million in 2025, supported by strong innovation in regenerative medicine and the country's leadership in induced pluripotent stem cell-based therapeutic development. Japanese biopharmaceutical manufacturers emphasize highly standardized analytical validation to meet stringent product quality expectations for advanced therapies. Continuous investment in precision analytical technologies and translational research infrastructure is increasing the adoption of highly sensitive residual DNA testing across commercial and clinical manufacturing facilities.
The residual DNA testing market competitive landscape is moderately consolidated, with competition led by established life science companies, molecular diagnostics providers, and specialized analytical testing organizations. Market participants compete through sensitive detection technologies, validated assay portfolios, regulatory expertise, and comprehensive biopharmaceutical testing services. Strategic collaborations with biologics manufacturers and continuous innovation in PCR- and sequencing-based platforms further strengthen competitive positioning. The residual DNA testing market ecosystem is shaped by stringent global regulatory requirements, increasing outsourcing of analytical testing, and growing demand for standardized quality control solutions across biopharmaceutical manufacturing.
April 2026: Roche announced an agreement to acquire SAGA Diagnostics for up to USD 595 million, strengthening its ultra-sensitive DNA detection portfolio through digital PCR and sequencing technologies applicable to high-sensitivity DNA analysis.
September 2025: Bio-Rad Laboratories launched the Vericheck ddPCR Residual DNA Quantification Kit, designed for highly sensitive quantification of residual host-cell DNA in biopharmaceutical products, expanding its digital PCR portfolio for biologics quality control applications.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanashri Bhapakar is a Senior Research Associate with 3+ years of experience in the Biotechnology sector. She focuses on tracking innovation trends, R&D breakthroughs, and market opportunities within biopharmaceuticals and life sciences. Dhanashri’s deep industry knowledge enables her to provide precise, data-backed insights that help companies innovate and compete effectively in global biotech markets.
We are featured on:
sales@straitsresearch.com